NIPERs focuses on research, 3D products to fight COVID19

NIPER-Raebareli has also initiated a mega project with IIT and an industrial partner in the development of new immuno-booster formulation utilizing traditionally used shrubs. NIPER Kolkata is working on an indigenous cost-effective ICU VENTILATOR in collaboration with CSIR CECRI and a private manufacturer.

Published On 2020-05-16 04:45 GMT   |   Update On 2020-05-16 04:46 GMT
Advertisement

New Delhi: A large number of multi-faceted research proposals have been submitted by various National Institutes of Pharmaceutical Education and Research (NIPERs), towards the containment, identification, and treatment of COVID-19 to relevant agencies for approval.

The key themes of these proposals include the design of protease targeting COVID-19 antiviral agents (NIPER-Mohali), computationally guided drug-repurposing using the FDA approved drug-database (NIPER-Mohali and Raebareli), analysis of pro-drug to drug conversion of Remdesvir (NIPER, Mohali), adjuvant-therapy based nasal spray for ailing patients (NIPER-Hyderabad), quantum-dot based and conductivity based biosensor development for rapid COVID-19 (NIPER-Ahmedabad) testing, and an interesting study about the control of strokes incidence during Covid-19.

Advertisement

NIPER-Raebareli has also initiated a mega project with IIT and an industrial partner in the development of new immuno-booster formulation utilizing traditionally used shrubs. NIPER Kolkata is working on an indigenous cost-effective ICU VENTILATOR in collaboration with CSIR CECRI and a private manufacturer.

National Institutes of Pharmaceutical Education and Research (NIPERs) are the institutes of national importance under the aegis of the Department of Pharmaceutical, Ministry of Chemicals and Fertilizers. The seven institutes are functional at Ahmadabad, Hyderabad, Hajipur, Kolkata, Guwahati, Mohali, and Raebareli.


A meeting of all the Directors and Chairmen of the institutions through video conferencing was held under the chairmanship of Dr P D Vaghela, Secretary, Pharmaceuticals here to review their performance in research & innovation activities especially with regard to the ways in which NIPERs have and can contribute in country's fight against COVID-19 pandemic.

Director, NIPER Guwahati informed about the fabrication of prototypes for 3D printed face-shields, a "hands-free object" for the touch-less opening of doors, drawers & elevators, antiviral masks as well as skin-friendly herbal sanitizers. He informed that industrial-scale manufacturing of these products is being done in collaboration with Hindustan Antibiotics Limited, a departmental PSU. At NIPER Mohali, in association with the Government of Punjab, steps have been initiated to set-up an RT-PCR based COVID-19 testing facility to expedite COVID-19 confirmatory tests in the state.

Dr Vaghela mentioned that all COVID-19 related research and product development initiatives should be done briskly to provide help to the needy at the earliest.

In particular, he stressed that all licensing and commercialization aspects of the developed solutions at NIPERs should be coordinated through regulatory agencies on priority so that the products reach the market in this hour of need. Through these research efforts and societal participation in helping the people, NIPERs are committed to work in solidarity with different groups and serve the country in the best possible way.

Read also: Cipla becomes 2nd firm to enter tie-up with Gilead to make remdesivir in India

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News